Egidio G. Del Fabbro, MD
Director of Palliative Care Program
Associate Professor of Internal Medicine
Division of Hematology/Oncology and Palliative Care
Virginia Commonwealth University
1101 East Marshall Street
Box 980230 Sanger Hall 6030 Richmond
VA 23298-0230, USA
Egidio Del Fabbro, MD, is the Program Director of Palliative Care at Virginia Commonwealth University Massey Cancer Center. Dr. Del also serves as an Associate Professor of Internal Medicine within the Division of Hematology, Oncology and Palliative Care of the Department of Internal Medicine at the VCU School of Medicine. He has published more than 60 peer-reviewed papers, abstracts and book chapters related to Palliative Care. He has received funding from the American Cancer Society to explore the effect of testosterone replacement in male patients with advanced cancer. He is also Editor of the Oxford University textbook Nutrition and the Cancer Patient.
Dr. Del Fabbro received his medical degree from the University of the Witwatersrand in Johannesburg, South Africa in 1990. In 1998, he completed his residency in Internal Medicine at Barnes-Jewish Hospital, Washington University, St. Louis.
He completed a fellowship at MD Anderson Cancer Center in the department of Palliative Care and Rehabilitation and was director of the Cachexia clinic at MD Anderson from 2005 to 2012.
His clinical research is focused on therapeutic interventions for symptoms such as poor appetite and cancer-related fatigue.
MEMBERSHIP IN SCIENTIFIC OR PROFESSIONAL SOCIETIES
2008 – present Member, American Society of Clinical Oncology (ASCO)
2008 – present Member, Multinational Association of Supportive Care in Cancer (MASCC)
4/2008 – present Member, American Association of Hospice and Palliative Medicine (AAHPM)
4/2008 – present Member, American College of Physicians
2008 – 2012 Member, Harris County Medical Association Houston, TX
2006 Member, Texas Medical Association
SCIENTIFIC AND SCHOLARLY ACTIVITIES EXPERT SERVICES
APPOINTMENTS AND RESPONSIBILITIES INCLUDING COMMITTEE AND BOARD APPOINTMENTS
2013 – Present LEAD focus group member, Leadership Development Program, American
2013 – Present Core Advisor, Advance Care Planning Richmond Academy of Medicine Richmond, VA
2013 Member, Virginia Commonwealth University Joint Delirium & Safe Mobility Group Richmond, VA
2012 – Present Co-chair, Virginia Commonwealth University Advance Care Planning, Palliative Care and Hospice Committee Richmond, VA
2012 – Present Virginia Commonwealth University Massey Cancer Center Division Leadership Council Richmond, VA
2012 – Present Virginia Commonwealth University Massey Cancer Center Clinical Oncology Services Executive Committee Richmond, VA
2012 – Present Member, Alliance for Clinical Trials in Oncology, Symptom Intervention Committee
6/2012 – Present Member, American Academy of Hospice and Palliative Medicine (AAHPM) Steering Committee
2012 – 2013 Member, Data Safety Monitoring Board (DSMB) for Kangliate trial : Efficacy and Safety of oral Kangliate (KLTc) Gelcap in Men with Prostate Cancer
2012 Virginia Commonwealth University Massey Cancer Center Clinical Trial Concept Review Committee Richmond, VA
2010 – 2012 Member, American Academy of Hospice and Palliative Medicine (AAHPM) Research Committee, Glenview, IL
2010 Consultant, GlaxoSmithKline Houston, TX
2008 – 2011 Appointed to American Association of Hospice and Palliative Medicine AAHPM Leadership Education and Academic Development Program (LEAD)
2007 – 2012 Member, University of Texas M.D. Anderson Cancer Center Clinical Research
2007 – 2008 Member, University of Texas M.D. Anderson Cancer Center Palliative Care Promotion Committee Houston, TX
2007 – 2008 Member, University of Texas M.D. Anderson Cancer Center Palliative Car Promotion Committee Houston, TX
Research Publications, peer reviewed (print or other media)
Original Research Articles
1.Dalal S, Del FE, Bruera E. Symptom control in palliative care Part I: oncology as a paradigmatic example. J Palliat Med. 2006; 9(2): 391-408.
2.Del FE, Dalal S, Bruera E. Symptom control in palliative care Part II: cachexia/anorexia and fatigue. J Palliat Med. 2006; 9(2): 409-421. doi:
3. Del FE, Dalal S, Bruera E. Symptom control in palliative care Part III: dyspnea and delirium. J Palliat Med. 2006; 9(2): 422-436. doi: 10.1089/jpm.2006.9.422
4. Del FE, Reddy SG, Walker P, Bruera E. Palliative sedation when the family and consulting service see no alternative. J Palliat Med. 2007; 10(2): 488-492.
5. Dev R, Del FE, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer. 2007; 110(6): 1173-1177.
6. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med. 2008; 11(2): 191-197. doi: 10.1089/jpm.2007.0094.
7. Fadul N, Elsayem A, Palmer JL, et al. Supportive versus palliative care: whats in a name: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer. 2009; 115(9): 2013-2021. doi: 10.1002/cncr.24206
8. Dalal S, Del FE, Bruera E. Is there a role for hydration at the end of life. Curr Opin Support Palliat Care. 2009; 3(1): 72-78. doi: 10.1097/SPC.0b013e32832531a5
9. Del FE, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010; 39(6): 1016-1024. doi: 10.1016/j.jpainsymman.2009.09.021
10. Dev R, Hui D, Dalal S, et al. Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer. J Pain Symptom Manage. 2011; 41(4): 788-795. doi: 10.1016/j.jpainsymman.2010.06.021
11. Dev R, Del FE, Bruera E. Patient-controlled analgesia in patients with advanced cancer. Should patients be in control? J Pain Symptom Manage. 2011; 42(2): 296-300. doi: 10.1016/j.jpainsymman.2010.11.020
12. Dev R, Parsons HA, Palla S, Palmer JL, Del FE, Bruera E. Undocumented alcoholism and its correlation with tobacco and illegal drug use in advanced cancer patients. Cancer. 2011; 117(19): 4551-4556. doi: 10.1002/cncr.26082
13. Del FE, Hui D, Dalal S, Dev R, Nooruddin ZI, Bruera E. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med. 2011; 14(9): 1004-1008. doi: 10.1089/jpm.2011.0098
14. Dev R, Del FE, Schwartz GG, et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist. 2011; 16(11): 1637-16341. doi: 10.1634/theoncologist.2011-0151
15. Hui D, Kilgore K, Nguyen L,et al. The accuracy of probabilistic versus temporal clinician prediction of survival for patients with advanced cancer: a preliminary report. Oncologist. 2011; 16(11): 1642-1648. doi: 10.1634/theoncologist.2011-0173
16. Hui D, Kilgore K, Fellman B, et al. Development and cross-validation of the in-hospital mortality prediction in advanced cancer patients score: a preliminary study. J Palliat Med. 2012; 15(8): 902-909. doi: 10.1089/jpm.2011.0437
17. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012; 44(2): 181-191. doi: 10.1016/j.jpainsymman.2011.09.010
18. Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia cachexia symptoms: results of a double blind placebo controlled randomized study. J Palliat Med. 2012; 15(10): 1059-1064. doi: 10.1089/jpm.2012.0146
19. Dev R, Del FE, Miles M, Vala A, Hui D, Bruera E. Growth of an academic palliative medicine program: patient encounters and clinical burden. J Pain Symptom Manage. 2013; 45(2): 261-271. doi: 10.1016/j.jpainsymman.2012.02.015
20. Del FE, Dev R, Cabanillas ME, et al. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother. 2012; 24(4): 221-225. doi: 10.1179/1973947812Y.0000000022
21. Vigano A, Del FE, Bruera E, Borod M. The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients. Crit Rev Oncog. 2012; 17(3): 293-303.
22. Del FE, Parsons H, Warneke CL, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012; 17(10): 1240-1245. doi: 10.1634/theoncologist.2012-0169
23. Del FE, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo controlled trial. J Clin Oncol. 2013; 31(10): 1271-1276. doi: 10.1200/JCO.2012.43.6766
24. Del FE, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013; 21(9): 2599-2607. doi: 10.1007/s00520-013-1832-5.
25. Dev R, Coulson L, Del FE, et al. A Prospective Study of Family Conferences: Effects of Patient Presence on Emotional Expression and End-of-life Discussions. J Pain Symptom Manage. 2013; 46(4): 536-545. doi: 10.1016/j.jpainsymman.2012.10.280
26. Garcia JM, Jatoi A, Del FE. The potential of ghrelin in cancer anorexia-cachexia. Eur Oncol Haematol. 2013; 9(2): 77-83.
27. Del FE. Assessment and management of chemical coping in cancer patients. J Clin Oncol. doi: 10.1200/JCO.2013.52.5170
28. Jennings C, Cassel JB, Fletcher DM, et al. Response to pain management among patients with active cancer, no evidence of disease, or chronic malignant pain in an outpatient palliative care clinic. J Palliat Med. 2013.
29. Dev R, Del FE, Bruera E. Outcomes of novel trials for cancer cachexia. Clin Invest. 2013.
30. Dev R, Hui D, Del FE, DelgadoGuay MO, Dalal S, Bruera E. The association among hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer. 2013. doi: 10.1002/cncr.28619
31. Dev R, Bruera E, Del FE. When and When Not to Use Testosterone for Palliation in Cancer Care. Current Oncology Reports. 2014. doi: 10.1007/s11912-014-0378-0